| 1 |
7,311,910 |
|
Methods for treating cancer and infectious disease by blocking CTLA4-B7interactions |
| 2 |
7,887,804 |
|
Methods for treating disease-states associated with RG1 using immunoconjugates |
| 3 |
7,893,217 |
|
Isolated human antibodies that bind epitopes on RG1 |
| 4 |
7,972,798 |
|
Method for identifying diabetic patients at increased risk for pathological complications |
| 5 |
8,007,827 |
|
Pharmaceutical dosage forms having immediate release and/or controlled release properties |
| 6 |
8,058,395 |
|
Chimeric protein comprising a green fluorescent ptotein fused to a transcription factor |
| 7 |
8,207,188 |
|
Treatment of diseases modulated by a H4 receptor agonist |
| 8 |
8,207,292 |
|
Treatment of COPD, gastro-esophageal reflux disease (GERD), food allergies and other gastrointestinal conditions and disorders ameliorated by proper histamine management using a combination of histidine decarboxylase inhibitors, LRA drugs, anti-H1 and/or anti-H2 drugs |
| 9 |
8,241,863 |
|
Identification of an evolutionarily conserved pathway mediating transrepression of inflammatory response genes by nuclear receptors |
| 10 |
8,263,068 |
|
Modified cells expressing a protein that modulates activity of bHLH proteins, and uses thereof |
| 11 |
8,377,474 |
|
Controlled release formulations of levodopa and uses thereof |
| 12 |
8,586,307 |
|
Methods for diagnosing epigenetic, transgenerational effects of environmental toxicants on mammalian germ-lines and treating associated diseases |
| 13 |
8,709,421 |
|
Combination of the application of antibodies for immunostimulation together with glucocorticoids |
| 14 |
8,883,502 |
|
Expandable cell source of neuronal stem cell populations and methods for obtaining and using them |
| 15 |
8,920,789 |
|
Use of polymer D-lactic acid (PDLA) or equivalents thereof to inhibit growth of cancer cells and diagnose cancers |
| 16 |
8,969,077 |
|
Neuronal specific targeting of caveolin expression to restore synaptic signaling and improve cognitive function in the neurodegenerative brain and motor function in spinal cord |
| 17 |
8,999,349 |
|
HMGB1-derived peptides enhance immune response to antigens |
| 18 |
9,119,832 |
|
Methods of treating mild brain injury |
| 19 |
9,168,275 |
|
Method of treating gastrointestinal diseases associated with species of genus Clostridium |
| 20 |
9,283,272 |
|
Targeting intracellular target-binding determinants with intracellular antibodies |
| 21 |
9,382,376 |
|
Use of polymer D-lactic acid (PDLA) or equivalents thereof to inhibit growth of cancer cells and diagnose cancers |
| 22 |
9,394,350 |
|
HLA-A2 tumor associated antigen peptides and compositions |
| 23 |
9,744,175 |
|
Compositions of combinations of non-covalent DNA binding agents and anti-cancer and/or anti-inflammatory agents and their use in disease treatment |
| 24 |
9,913,884 |
|
HLA-A2 tumor associated antigen peptides and compositions |
| 25 |
9,989,519 |
|
Method for determining in vitro bioequivalence of a sucralfate suspension sample to a sucralfate suspension reference listed drug (RLD) |
| 26 |
10,350,280 |
|
Methods To Analyze Genetic Alterations In Cancer To Identify Therapeutic Peptide Vaccines And Kits Therefore |
